GlassScriptPhysician profile
Lawrence G Shore
NPI 1053347815
$654.95
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $130.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.12 | 2019 | |
| Merck Sharp & Dohme LLC | $85.03 | 2019 | |
| Glaxosmithkline, LLC. | $68.55 | 2019 | |
| Astellas Pharma US INC | $47.54 | 2019 | |
| Lilly USA, LLC | $42.58 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.57 | 2019 | |
| Amgen INC. | $26.57 | 2019 | |
| Insulet Corporation | $25.80 | 2019 | |
| Daiichi Sankyo INC. | $24.01 | 2019 | |
| Novo Nordisk INC | $19.65 | 2019 | |
| Bausch Health US, LLC | $19.08 | 2019 | |
| Pulmonx Corporation | $18.14 | 2019 | |
| Endo Pharmaceuticals INC. | $17.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.70 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Shore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.